---
title: "Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: BCA101X1101"
description: "Formulary evidence on Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: BCA101X1101. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 104 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence/bca101x1101"
published: "2026-11-15T21:46:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: BCA101X1101

<a id="heading-3.1.2"></a>

## 3.1.2 BCA101X1101

<a id="heading-3.1.2.1"></a>

### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

#### Registry title and purpose

> “First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors”
> “The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ.”

Source: [ClinicalTrials.gov NCT04429542](https://clinicaltrials.gov/study/NCT04429542)

<a id="topic-3.1.2.1-2"></a>

#### Dose escalation: safety, tolerability, and maximum tolerated dose

> “The primary objective of this study was to assess safety and tolerability and to determine the MTD of ficerafusp alfa as monotherapy and in combination with pembrolizumab.”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-3.1.2.1-3"></a>

#### First-line HNSCC expansion cohort at 1500 mg weekly: safety and antitumor activity

> “Does ficerafusp alfa show acceptable safety and antitumor activity when combined with pembrolizumab for first-line treatment of PD-L1–positive recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)?”
> “The primary objective was to characterize safety and tolerability in the safety set (patients who received ≥1 dose of study treatment), including TEAEs and TRAEs (defined as any TEAE deemed related to ficerafusp alfa or pembrolizumab).”
> “The secondary objective for the HNSCC dose-expansion cohort was to explore the antitumor activity of ficerafusp alfa in the efficacy-evaluable set (EES; treated patients with ≥1 postbaseline scan).”
> “Exploratory objectives included evaluation of pharmacodynamic markers.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.1-4"></a>

#### Integrated analysis of the three first-line dose cohorts

> “Herein we present an integrated analysis of all three dose cohorts with extended follow-up, highlighting TGF-β inhibition, depth of response, long-term survival outcomes, and sustained disease control”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

> “This is the first report of long-term efficacy follow-up across two cohorts of ficerafusp alfa.”

Source: [Wong et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6040)

<a id="heading-3.1.2.2"></a>

### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

#### Registry study dates

| Study characteristic | Quoted record |
| --- | --- |
| Study start (actual) | “2020-06-01” |
| Primary completion (estimated) | “2027-10-31” |
| Study completion (estimated) | “2028-03-30” |

Source: [ClinicalTrials.gov NCT04429542](https://clinicaltrials.gov/study/NCT04429542)

<a id="topic-3.1.2.2-2"></a>

#### Registry study sites

| Country | Quoted site |
| --- | --- |
| United States | “Moores Cancer Center UC San Diego Health” |
| United States | “Keck School of Medicine of USC” |
| United States | “University of California, Davis Comprehensive Cancer Center” |
| United States | “H. Lee Moffitt Cancer Center and Research Institute, Inc” |
| United States | “Dana Farber/Partners Cancer Care Inc” |
| United States | “Memorial Sloan Kettering” |
| United States | “Columbia University Herbert Irving Comprehensive Cancer Center” |
| United States | “Levine Cancer Institute” |
| United States | “Cleveland Clinic” |
| United States | “UPMC Hillman Cancer Center” |
| United States | “Rhode Island Hospital” |
| United States | “Medical University of South Carolina, Hollings Cancer Center” |
| United States | “Vanderbilt University Medical Center” |
| United States | “MD Anderson Cancer Center” |
| Australia | “Chris O'Brien Lifehouse” |
| Australia | “Calvary Mater Newcastle” |
| Australia | “Austin Hospital” |
| Australia | “Peter MacCallum Cancer Centre” |
| Canada | “Princess Margaret Cancer Centre” |
| Canada | “Centre hospitalier de l'Université de Montréal (CHUM)” |

Source: [ClinicalTrials.gov NCT04429542](https://clinicaltrials.gov/study/NCT04429542)

<a id="topic-3.1.2.2-3"></a>

#### Dose escalation enrollment period and data cutoff

> “Between June 25, 2020, and June 9, 2022, 61 patients were enrolled”
> “The data cutoff for the data reported was April 17, 2024.”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-3.1.2.2-4"></a>

#### First-line 1500 mg weekly cohort enrollment period, data snapshot, and geography

> “Between February 2022 and April 2023, 51 patients were screened”
> “As of the data snapshot (March 20, 2025)”
> “limited geographic scope (the United States and Canada)”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.2-5"></a>

#### First-line 750 mg weekly cohort data snapshot

> “Data snapshot: July 9, 2025.”

Source: [Kaczmar et al. (2025)](https://www.bicara.com/wp-content/uploads/2025/12/750-mg-ESMO-Asia-Congress-2025-12.6.25.pdf)

<a id="topic-3.1.2.2-6"></a>

#### First-line 2000 mg every 2 weeks cohort data snapshot

> “Data snapshot: December 16, 2025.”

Source: [Zandberg et al. (2026)](https://www.bicara.com/wp-content/uploads/2026/02/Zandberg_2026_MHNCS_Pres_2000-mg-Cohort_Edited.pdf)

<a id="topic-3.1.2.2-7"></a>

#### Integrated analyses of the first-line cohorts: data cutoffs

> “As of December 16, 2025, 61 HPV-neg pts were treated in two cohorts (750 mg, n=31; 1500 mg, n=30); 58 pts were efficacy evaluable.”

Source: [Wong et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6040)

> “As of March 31, 2026, 91 patients received the study drug (safety analysis [SA] set) and 85 were evaluable for efficacy (efficacy evaluable [EE] set)”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="heading-3.1.2.3"></a>

### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

#### Registry design: nonrandomized, open-label, parallel assignment

| Study characteristic | Quoted record |
| --- | --- |
| Protocol number | “BCA101X1101” |
| Merck study identifier | “KEYNOTE-E28” |
| Allocation | “Non-Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT04429542](https://clinicaltrials.gov/study/NCT04429542)

<a id="topic-3.1.2.3-2"></a>

#### Registry design: dose escalation (Part A) followed by expansion cohorts (Part B)

> “This is a Phase 1/1b, open-label study, which consists of dose escalation parts (Part A) followed by expansion cohorts (Part B) for both single agent BCA101 and combination BCA101 plus pembrolizumab.”
> “Dose escalation (Part A) of combination BCA101 and pembrolizumab consists of subjects with either Squamous Cell Carcinoma of the Head and Neck (HNSCC) or Squamous Cell Carcinoma of the Anal Canal (SCCAC) whose tumors are refractory to standard of care or for whom no standard of care is available.”
> “Once the maximum tolerated dose (MTD) / recommended dose (RD) of single agent BCA101 is determined, the study will continue with expansion cohorts (Part B) with select tumor types.”
> “Planned expansion cohorts for the combination of BCA101 and pembrolizumab include: 1) HNSCC and 2) SCCAC.”

Source: [ClinicalTrials.gov NCT04429542](https://clinicaltrials.gov/study/NCT04429542)

<a id="topic-3.1.2.3-3"></a>

#### Dose escalation: parallel 3 + 3 design with backfilling

> “Dose escalation in this first-in-human phase I clinical trial (BCA101X1101) followed a parallel 3 + 3 design for both ficerafusp alfa monotherapy and ficerafusp alfa in combination with pembrolizumab”
> “Backfilling of up to six additional patients was allowed once acceptable safety had been demonstrated for the respective dose level.”
> “Once the first two dose levels of ficerafusp alfa monotherapy were determined to be safe, enrollment in the combination started.”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-3.1.2.3-4"></a>

#### First-line HNSCC dose-expansion cohort reported separately from escalation

> “This open-label, multicenter, prospective, nonrandomized, first-in-human, phase I/Ib study (ClinicalTrials.gov identifier: NCT04429542) evaluated ficerafusp alfa as monotherapy and in combination with pembrolizumab for patients with advanced EGFR-driven solid tumors.”
> “After determination of the recommended dose, expansion cohorts were enrolled”
> “dose-escalation patients were not included in the dose-expansion cohort”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.3-5"></a>

#### Three first-line HPV-negative dose-expansion cohorts under a Simon two-stage design

> “Part B: Dose expansion in 1L R/M HPV-negative HNSCC”
> “(Simon 2-stage design)”
> “Preliminary evaluations of the 750 mg weekly (QW), 1500 mg QW, and 2000 mg every 2 weeks (Q2W) cohorts successfully established early clinical activity and tolerability of the bifunctional mechanism”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="topic-3.1.2.3-6"></a>

#### Rationale for the 750 mg weekly and 2000 mg every 2 weeks cohorts

> “This is one of two doses being evaluated for optimal biologic dose in the ongoing phase 2/3 FORTIFI-HN01 study”

Source: [Kaczmar et al. (2025)](https://www.bicara.com/wp-content/uploads/2025/12/750-mg-ESMO-Asia-Congress-2025-12.6.25.pdf)

> “Ficerafusp alfa’s half-life of ~ 8 days supports the rationale to explore less frequent dosing schedules”

Source: [Zandberg et al. (2026)](https://www.bicara.com/wp-content/uploads/2026/02/Zandberg_2026_MHNCS_Pres_2000-mg-Cohort_Edited.pdf)

<a id="heading-3.1.2.4"></a>

### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

#### Registry criteria for the first-line HNSCC combination cohort (expansion cohort 2)

> “Expansion Cohort 2: Head and Neck Squamous Cell Carcinoma (HNSCC), metastatic or unresectable, recurrent with a Combined Positive Score (CPS) equal to or greater than 1, as determined by an CLIA-approved laboratory test.”
> “Primary tumor locations of oropharynx, oral cavity, hypopharynx, or larynx.”
> “Participants may not have a primary tumor site of nasopharynx (any histology).”
> “Patients must have no prior systemic therapy administered in the recurrent or metastatic setting (with the exception of systemic therapy completed >6 months prior if given as part of multimodal treatment for locally advanced disease) or prior history of immune checkpoint inhibitors with the exception of neoadjuvant therapy (>6 months prior to study drug initiation).”
> “No prior history of anti-EGFR antibodies (with the exception of radiosensitizing agents and multimodal treatment for locally advanced disease).”
> “Patients must provide tissue for PD-L1 biomarker analysis from a core or excisional biopsy (fine needle aspirate is not sufficient): A newly obtained biopsy (within 90 days prior to start of study treatment) is preferred but an archival sample is acceptable.”
> “Patients must have results from testing of human papillomavirus (HPV) status for oropharyngeal cancer”

Source: [ClinicalTrials.gov NCT04429542](https://clinicaltrials.gov/study/NCT04429542)

<a id="topic-3.1.2.4-2"></a>

#### Registry criteria for the HNSCC cohort with CPS less than 1 (expansion cohort 6)

> “Expansion Cohort 6: Head and Neck Squamous Cell Carcinoma (HNSCC), metastatic or unresectable, recurrent with a Combined Positive Score (CPS) less than 1, as determined by PD-L1 IHC 22C3 pharmDx.”

Source: [ClinicalTrials.gov NCT04429542](https://clinicaltrials.gov/study/NCT04429542)

<a id="topic-3.1.2.4-3"></a>

#### Registry criteria common to all cohorts

> “Patient must have a performance status of ≤1 on the Eastern Cooperative Oncology Group Performance Scale.”
> “Patient must have measurable disease amendable to biopsy and be willing to undergo both a pre-treatment and on-treatment biopsy”
> “Prior treatment with any anti-TGFβ therapy.”
> “Prior history of Grade ≥ 2 intolerance or hypersensitivity reaction to cetuximab or other anti-EGFR therapy or other murine proteins or prior discontinuation of therapy in the setting of toxicity related to treatment.”

Source: [ClinicalTrials.gov NCT04429542](https://clinicaltrials.gov/study/NCT04429542)

<a id="topic-3.1.2.4-4"></a>

#### First-line 1500 mg weekly cohort: published eligibility, PD-L1 assay, and HPV determination

> “Eligible study patients were age 18 years and older and had pathologically confirmed, unresectable R/M HNSCC (including primary tumors in the oral cavity, oropharynx, hypopharynx, and larynx)”
> “Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1; and adequate hepatic, renal, and hematologic function.”
> “Patients with prior systemic therapy for R/M disease were ineligible.”
> “Patients with prior platinum chemotherapy or anti-EGFR or anti–PD-1 treatment for locoregionally advanced HNSCC completed >6 months before enrollment were eligible.”
> “All patients were required to have tumor PD-L1 CPS ≥1 (assessed locally in archival or fresh samples using the 22C3 immunohistochemistry or other validated assay), and for oropharyngeal primary tumors, p16 immunohistochemistry or HPV molecular test result.”
> “Twelve oropharyngeal tumors were classified as HPV-positive, whereas all oral cavity, hypopharynx, and larynx tumors were considered HPV-negative per current clinical standard.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.4-5"></a>

#### Integrated first-line HPV-negative analysis: key inclusion criteria

> “Primary tumor in oral cavity, oropharynx, larynx, or hypopharynx”
> “PD-L1 CPS was assessed locally in archival or fresh samples using the 22C3 immunohistochemistry or other validated assay.”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

> “Two dose-expansion cohorts of an ongoing phase 1/1b study (NCT04429542) enrolled adults with 1L R/M HNSCC with PD-L1 CPS ≥1.”

Source: [Wong et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6040)

<a id="topic-3.1.2.4-6"></a>

#### First-line 750 mg weekly and 2000 mg every 2 weeks cohorts: HPV-negative population

> “1L R/M HNSCC, HPV-negative”
> “Oral cavity, oropharynx, larynx, and hypopharynx”

Source: [Kaczmar et al. (2025)](https://www.bicara.com/wp-content/uploads/2025/12/750-mg-ESMO-Asia-Congress-2025-12.6.25.pdf)

> “Oral cavity, oropharynx, larynx, or hypopharynx”

Source: [Zandberg et al. (2026)](https://www.bicara.com/wp-content/uploads/2026/02/Zandberg_2026_MHNCS_Pres_2000-mg-Cohort_Edited.pdf)

<a id="topic-3.1.2.4-7"></a>

#### Dose escalation combination cohort eligibility

> “For the dose-escalation cohort receiving ficerafusp alfa in combination with pembrolizumab, tumor types included recurrent unresectable or metastatic (R/M) HNSCC and SCAC.”
> “Patients were eligible regardless of the number of previous lines of systemic therapy.”
> “EGFR tumor tissue expression testing was not required for participation.”
> “Patients were ineligible if they had a history of gastrointestinal bleeding 4 weeks prior to enrollment, a history of clinically significant cardiac valvular disease, previous treatment with anti–TGF-β therapy, or a prior history of grade ≥2 intolerance or hypersensitivity reaction to cetuximab or other anti-EGFR therapy”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="heading-3.1.2.5"></a>

### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

#### Registry arms

| Arm | Quoted arm description |
| --- | --- |
| BCA101 monotherapy | “Route: IV Infusion Frequency: QW Current Dose: 1500mg” |
| BCA101 plus pembrolizumab | “Route: IV Infusion Frequency: Q3W Dose: 200mg” |

Source: [ClinicalTrials.gov NCT04429542](https://clinicaltrials.gov/study/NCT04429542)

<a id="topic-3.1.2.5-2"></a>

#### Dose escalation: dose range, starting doses, and infusion

> “At escalating doses in a parallel 3 + 3 design, patients with EGFR-driven advanced solid tumors received weekly intravenous ficerafusp alfa as monotherapy (64–1,500 mg) or in combination (240–1,500 mg) with pembrolizumab (200 mg i.v. every 3 weeks).”
> “The starting dosage of ficerafusp alfa in monotherapy for patients enrolled in the study was set at 64 mg i.v. administered continuously once weekly.”
> “The selected starting dosage followed the International Council for Harmonization S9 guidelines.”
> “Ficerafusp alfa was administered as an infusion over 120 minutes.”
> “The starting dosage of ficerafusp alfa in combination with pembrolizumab was 240 mg i.v. once weekly.”
> “Pembrolizumab 200 mg i.v. was administered after ficerafusp alfa as a 30-minute infusion every 3 weeks (cycle length, 21 days).”
> “64, 240, 500, 750, 800, 1,000, 1,250, and 1,500 mg”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-3.1.2.5-3"></a>

#### First-line 1500 mg weekly regimen and dose modification rules

> “Eligible patients received pembrolizumab 200 mg intravenously (IV) on day 1 and ficerafusp alfa 1,500 mg IV on days 1, 8, and 15 in 21-day cycles until disease progression, death, unacceptable toxicity, loss to follow-up, or withdrawal of consent.”
> “Treatment beyond progression was permitted at the discretion of the treating investigator if the patient was deriving clinical benefit.”
> “Pembrolizumab was interrupted or discontinued (dose reduction not permitted) for grade ≥3 immune-related adverse events (AEs) per investigator assessment.”
> “The infusion rate of ficerafusp alfa was reduced by 50% for grade 1/2 or nonserious infusion-related reactions (IRRs); ficerafusp alfa was permanently discontinued for grade ≥3 or serious IRRs.”
> “Grade ≥3 AEs resulted in interruption, dose modification (ficerafusp alfa only), or permanent discontinuation according to study drug attribution.”
> “Topical steroids and/or antibiotics were recommended as prophylaxis or treatment for acneiform dermatitis.”
> “Patients who discontinued one study drug for any reason other than disease progression could continue the other per investigator discretion.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.5-4"></a>

#### First-line 750 mg weekly regimen

> “Patients received ficerafusp alfa 750 or 1500 mg IV on D1, 8, and 15 plus pembrolizumab (pembro) 200 mg IV Q3W.”

Source: [Wong et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6040)

> “Ficerafusp alfa 750 mg QW + Pembrolizumab 200 mg Q3W”

Source: [Kaczmar et al. (2025)](https://www.bicara.com/wp-content/uploads/2025/12/750-mg-ESMO-Asia-Congress-2025-12.6.25.pdf)

<a id="topic-3.1.2.5-5"></a>

#### First-line 2000 mg every 2 weeks regimen

> “Ficerafusp alfa 2000 mg Q2W + Pembrolizumab 400 mg Q6W”

Source: [Zandberg et al. (2026)](https://www.bicara.com/wp-content/uploads/2026/02/Zandberg_2026_MHNCS_Pres_2000-mg-Cohort_Edited.pdf)

<a id="topic-3.1.2.5-6"></a>

#### Escalation and expansion regimens in the integrated analysis

> “Ficerafusp alfa 240-1500 mg QW IV”
> “Pembrolizumab 200 mg Q3W IV”
> “MTD not reached”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="heading-3.1.2.6"></a>

### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

#### 3.1.2.6.1 Rationale for Using Dose-limiting Toxicities and Adverse Events as the Primary Endpoints

<a id="topic-3.1.2.6.1-1"></a>

##### Registry primary outcomes

| Outcome | Quoted measure | Quoted time frame |
| --- | --- | --- |
| Safety | “Safety of BCA101 alone and BCA101 in combination with pembrolizumab: Incidence and severity of AEs and SAEs” | “24 months” |
| Tolerability | “Tolerability of BCA101 alone and BCA101 in combination with pembrolizumab: Incidence and severity of AEs and SAEs” | “24 months” |
| Dose-limiting toxicities | “Incidence of DLTs during the first cycle of treatment with BCA101 monotherapy or the combination of BCA101 and pembrolizumab.” | “21 days” |

Source: [ClinicalTrials.gov NCT04429542](https://clinicaltrials.gov/study/NCT04429542)

<a id="topic-3.1.2.6.1-2"></a>

##### Registry secondary outcomes and response criteria

| Outcome | Quoted description |
| --- | --- |
| Objective response rate | “Determine objective response rate in each part of the study, per RECIST v1.1 and iRECIST” |
| Clinical benefit rate | “Determine clinical benefit rate in each part of the study, per RECIST v1.1 and iRECIST” |
| Progression-free survival | “Determine PFS in each part of the study, per RECIST v1.1 and iRECIST” |
| Duration of response | “Determine duration of response in each part of the study, per RECIST v1.1 and iRECIST” |
| Overall survival | “Determine survival rates in each part of the study.” |
| Immunogenicity | “Incidence and titer of anti-drug-antibodies” |

Source: [ClinicalTrials.gov NCT04429542](https://clinicaltrials.gov/study/NCT04429542)

<a id="topic-3.1.2.6.1-3"></a>

##### Dose escalation: dose-limiting toxicity as the primary endpoint

> “The primary endpoint was the incidence of dose-limiting toxicities (DLT).”
> “DLTs were defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications occurring within the first 21 days of treatment with ficerafusp alfa”
> “Secondary objectives included the characterization of the pharmacokinetic (PK) and immunogenicity profile of ficerafusp alfa and preliminary antitumor activity of ficerafusp alfa as monotherapy and in combination with pembrolizumab as assessed by the investigator by RECIST version 1.1”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-3.1.2.6.1-4"></a>

##### First-line 1500 mg weekly cohort: safety as the primary endpoint and efficacy endpoint definitions

> “The primary end point was safety.”
> “Secondary end points included objective response rate (ORR), progression-free survival (PFS), duration of response (DOR), and overall survival (OS).”
> “End points included ORR; clinical benefit rate (CBR; best response of complete response [CR], partial response [PR], or stable disease [SD] for ≥5 weeks); DOR (time from first assessment of CR or PR to first documentation of progressive disease [PD] or death, whichever occurred earlier); and progression-free survival (PFS) and OS (time from study enrollment to the first occurrence of progression or death [whichever occurred earlier] or death, respectively).”
> “Imaging assessments were performed at baseline, every 6 weeks during treatment until cycle 13, then every 9 weeks thereafter.”
> “AEs were classified using preferred terms according to the Medical Dictionary for Regulatory Activities, and were graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 5.”
> “investigator-assessed according to RECIST v1.1”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.6.1-5"></a>

##### Safety findings informing subsequent trials

> “Safety findings from this phase I/Ib study have informed the design of subsequent studies of ficerafusp alfa and pembrolizumab, including mitigation strategies for AEs of special interest.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.6.1-6"></a>

##### Depth of response: definition

> “Deep response is defined as ≥80% tumor regression in target lesions vs baseline.”
> “Table shows investigator-assessed best overall response per RECIST 1.1.”

Source: [Zandberg et al. (2026)](https://www.bicara.com/wp-content/uploads/2026/02/Zandberg_2026_MHNCS_Pres_2000-mg-Cohort_Edited.pdf)

> “Deep response (≥80% tumor shrinkage)”

Source: [Kaczmar et al. (2025)](https://www.bicara.com/wp-content/uploads/2025/12/750-mg-ESMO-Asia-Congress-2025-12.6.25.pdf)

<a id="topic-3.1.2.6.1-7"></a>

##### Depth of response: rationale for exploratory analysis

> “Depth of response has been shown to correlate with prolonged progression free survival (PFS) and overall survival (OS) in several solid tumors. However, such data are limited in R/M HPV-negative HNSCC.”
> “In the pooled efficacy evaluable set from the three cohorts, we explored if the magnitude of tumor regression, comparing tumor regression ≥80% regression (defined as a deep response) vs. tumor regression 0 to <80%, is predictive of longer-term clinical outcomes (DOR, PFS, OS).”
> “This suggests that depth of response may represent a clinically meaningful surrogate for understanding long-term efficacy outcomes in HPV-negative HNSCC.”

Source: [Kaczmar et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6058)

<a id="topic-3.1.2.6.1-8"></a>

##### Objective response rate and depth of response as support for the pivotal interim analysis

> “the consistently high ORRs and depth of response validate the planned ORR-based interim analysis in the ongoing FORTIFI-HN01 trial”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="heading-3.1.2.7"></a>

### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

#### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

##### Registry planned enrollment across all cohorts

| Study characteristic | Quoted record |
| --- | --- |
| Enrollment (estimated) | “473” |

Source: [ClinicalTrials.gov NCT04429542](https://clinicaltrials.gov/study/NCT04429542)

<a id="topic-3.1.2.7.1-2"></a>

##### Dose escalation: participants enrolled

> “Among 61 patients (monotherapy, n = 46; combination, n = 15)”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-3.1.2.7.1-3"></a>

##### First-line 1500 mg weekly cohort: Simon two-stage sample size and participants analyzed

> “A Simon 2-stage optimal design was used, in which the treatment regimen warrants further evaluation if >3 objective responses were observed among the first 18 eligible patients.”
> “The regimen was deemed promising if >10/39 patients in the EES had an objective response.”
> “The design yielded 90.1% power to rule out a 19% CBR and detect a 38% ORR (using a one-sided exact binomial test with a type I error rate of 9.7%).”
> “Between February 2022 and April 2023, 51 patients were screened (Fig 1), 42 patients received ≥1 dose of study drug, and 39 patients were evaluable for efficacy.”
> “In efficacy-evaluable patients with HPV-negative (n = 28) or HPV-positive (n = 11) tumors”
> “The median follow-up was 26.3 months (range, 23.9-29.4).”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.7.1-4"></a>

##### First-line 750 mg weekly cohort: participants analyzed

> “Dose-expansion cohort (n=31)”
> “Efficacy-evaluable population (n=30)”

Source: [Kaczmar et al. (2025)](https://www.bicara.com/wp-content/uploads/2025/12/750-mg-ESMO-Asia-Congress-2025-12.6.25.pdf)

<a id="topic-3.1.2.7.1-5"></a>

##### First-line 2000 mg every 2 weeks cohort: participants analyzed

> “Dose-expansion cohort (N=30)”
> “EE set (N=27)”

Source: [Zandberg et al. (2026)](https://www.bicara.com/wp-content/uploads/2026/02/Zandberg_2026_MHNCS_Pres_2000-mg-Cohort_Edited.pdf)

<a id="topic-3.1.2.7.1-6"></a>

##### Integrated first-line HPV-negative analyses: participants analyzed and follow-up

> “In the 750 mg QW, 1500 mg QW, and 2000 mg Q2W cohorts, respectively:”
> “Patient numbers in the SA/EE populations were 31/30, 30/28, and 30/27”
> “Median (95% CI) follow-up was 20 (20-22), 36 (36-43) and 24 (12-27) months”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

> “85 patients with HPV-negative disease were efficacy evaluable across three cohorts (n=30, n=28, and n=27 at 750mg, 1500mg, and 2000mg doses of ficerafusp alfa, respectively).”

Source: [Kaczmar et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6058)

<a id="heading-3.1.2.7.2"></a>

#### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

##### Dose escalation analysis sets

> “Descriptive statistics were used to summarize all patient characteristics, treatment administration and compliance, efficacy endpoints, and safety parameters.”
> “The safety set included all patients who received at least one dose of study treatment, ficerafusp alfa or pembrolizumab.”
> “The dose-determining set included all patients in the safety set who enrolled during dose escalation and either experienced a DLT at any time during the DLT evaluation period (first 21 days) or had all required safety assessments without experiencing a DLT within the DLT evaluation period.”
> “The efficacy-evaluable set included all patients who received at least one dose of study treatment and had at least one post-baseline tumor assessment as defined in the protocol at or beyond the first post-baseline visit for tumor assessment.”
> “If a patient had progressive disease before the first post–baseline assessment visit, they were also included in the efficacy-evaluable set.”
> “The PK analysis set consisted of all patients who had at least one blood sample providing evaluable PK data.”
> “The duration of response analysis was performed using Kaplan–Meier methods.”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-3.1.2.7.2-2"></a>

##### First-line 1500 mg weekly cohort analysis sets and HPV subgroups

> “safety set (patients who received ≥1 dose of study treatment)”
> “efficacy-evaluable set (EES; treated patients with ≥1 postbaseline scan)”
> “PFS and OS were estimated using the Kaplan-Meier method.”
> “Efficacy was analyzed in the EES (n = 39).”
> “Samples collected from patients who missed a previous dose of ficerafusp alfa were excluded from pharmacodynamic analyses.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.7.2-3"></a>

##### Integrated first-line analysis restricted to HPV-negative participants

> “The 1500 mg QW cohort also enrolled HPV-positive patients, who were not included in the current analysis.”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="topic-3.1.2.7.2-4"></a>

##### Pooled efficacy-evaluable set for the depth of response analysis

> “Here we performed exploratory analyses to evaluate whether depth of response achieved with ficerafusp alfa and pembrolizumab is associated with prolonged duration of response (DOR), PFS and OS.”

Source: [Kaczmar et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6058)

<a id="heading-3.1.2.8"></a>

### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

#### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

##### Dose escalation: participants excluded from the efficacy-evaluable set

> “Of the 46 patients treated with ficerafusp alfa monotherapy, four patients did not have a post-baseline assessment and were excluded from the efficacy-evaluable population.”
> “Among the 15 patients treated with ficerafusp alfa in combination with pembrolizumab, 13 patients were RECIST 1.1 evaluable, and two patients discontinued treatment because of adverse events before the first post-baseline efficacy assessment”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-3.1.2.8.1-2"></a>

##### First-line 1500 mg weekly cohort: screening, treatment status, and follow-up

> “Between February 2022 and April 2023, 51 patients were screened (Fig 1), 42 patients received ≥1 dose of study drug, and 39 patients were evaluable for efficacy.”
> “As of the data snapshot (March 20, 2025), three patients (8%) remained on study treatment and 36 (92%) had discontinued, most often for PD (20 [51%]; Appendix Table A1); 12 (31%) remained in follow-up.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.1-3"></a>

##### First-line 1500 mg weekly cohort: reasons for treatment or study discontinuation

| Status or reason | Safety set (N = 42), No. (%) | Efficacy-evaluable set (n = 39), No. (%) |
| --- | --- | --- |
| Treatment ongoing | “3 (7)” | “3 (7)” |
| Treatment discontinuation | “39 (93)” | “36 (92)” |
| Treatment discontinuation: progression of disease | “21 (50)” | “20 (51)” |
| Treatment discontinuation: adverse event | “10 (24)” | “8 (21)” |
| Treatment discontinuation: patient withdrawal | “5 (12)” | “5 (13)” |
| Treatment discontinuation: investigator discretion | “3 (7)” | “3 (8)” |
| Study follow-up ongoing | “12 (29)” | “12 (31)” |
| Study follow-up discontinued | “30 (71)” | “27 (69)” |
| Study follow-up discontinued: death | “29 (69)” | “26 (67)” |
| Study follow-up discontinued: patient withdrawal | “1 (2)” | “1 (3)” |
| Study follow-up discontinued: lost to follow-up | “0” | “0” |

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.1-4"></a>

##### First-line 750 mg weekly cohort: participant not evaluable for efficacy

> “1 patient was not evaluable for efficacy due to early death unrelated to treatment.”

Source: [Kaczmar et al. (2025)](https://www.bicara.com/wp-content/uploads/2025/12/750-mg-ESMO-Asia-Congress-2025-12.6.25.pdf)

<a id="topic-3.1.2.8.1-5"></a>

##### First-line 1500 mg weekly cohort: participants on treatment at the most recent data cut

> “After a median follow-up of 36 months, median DOR in the 1500 mg QW cohort was of 21.7 months, with 10% of patients (n=3) remaining on active treatment.”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="heading-3.1.2.8.2"></a>

#### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

##### First-line HPV-negative dose cohorts at the March 2026 data cut

| Characteristic | 750 mg QW (N=31) | 1500 mg QW (N=30) | 2000 mg Q2W (N=30) |
| --- | --- | --- | --- |
| Age, median (min-max) | “64 (28-78)” | “63 (31-84)” | “63 (32-94)” |
| Male, n (%) | “20 (65)” | “19 (63)” | “20 (67)” |
| Female, n (%) | “11 (35)” | “11 (37)” | “10 (33)” |
| Oral cavity, n (%) | “19 (61)” | “14 (47)” | “19 (63)” |
| Oropharynx (HPV negative), n (%) | “4 (13)” | “8 (27)” | “6 (20)” |
| Hypopharynx, n (%) | “5 (16)” | “4 (13)” | “2 (7)” |
| Larynx, n (%) | “3 (10)” | “4 (13)” | “3 (10)” |
| CPS 1-19, n (%) | “12 (39)” | “15 (50)” | “15 (50)” |
| CPS ≥20, n (%) | “19 (61)” | “15 (50)” | “15 (50)” |
| Locoregional only, (%) | “16 (52)” | “9 (30)” | “19 (63)” |
| Distant metastatic only, (%) | “5 (16)” | “7 (23)” | “5 (17)” |
| Locoregional and distant metastatic, (%) | “10 (32)” | “14 (47)” | “6 (20)” |
| Target lesion diameter (mm) at baseline, median (min-max) | “41 (11-131)” | “49 (10-133)” | “33 (10-187)” |
| Sum of target lesion diameters >50 mm, n (%) | “10 (32)” | “14 (47)” | “11 (37)” |
| Sum of target lesion diameters >70 mm, n (%) | “4 (13)” | “8 (27)” | “7 (23)” |
| ECOG PS 0, n (%) | “11 (35)” | “11 (37)” | “10 (33)” |
| ECOG PS 1, n (%) | “20 (65)” | “19 (63)” | “20 (67)” |

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="topic-3.1.2.8.2-2"></a>

##### First-line 1500 mg weekly cohort by HPV status

| Characteristic | Participants (N = 42) | HPV-positive (n = 12) | HPV-negative (n = 30) |
| --- | --- | --- | --- |
| Age, years, median (range) | “63 (31-84)” | “65 (48-77)” | “63 (31-84)” |
| Male, No. (%) | “30 (71)” | “11 (92)” | “19 (63)” |
| Female, No. (%) | “12 (29)” | “1 (8)” | “11 (37)” |
| White/Caucasian, No. (%) | “34 (81)” | “10 (83)” | “24 (80)” |
| Black or African American, No. (%) | “3 (7)” | “1 (8)” | “2 (7)” |
| Asian, No. (%) | “1 (2)” | “0” | “1 (3)” |
| Multiple races, No. (%) | “1 (2)” | “0” | “1 (3)” |
| Race not reported, No. (%) | “3 (7)” | “1 (8)” | “2 (7)” |
| ECOG performance status 0, No. (%) | “15 (36)” | “4 (33)” | “11 (37)” |
| ECOG performance status 1, No. (%) | “27 (64)” | “8 (67)” | “19 (63)” |
| Oropharynx, No. (%) | “20 (48)” | “12 (100)” | “8 (27)” |
| Oral cavity, No. (%) | “14 (33)” | “0” | “14 (47)” |
| Hypopharynx, No. (%) | “4 (10)” | “0” | “4 (13)” |
| Larynx, No. (%) | “4 (10)” | “0” | “4 (13)” |
| CPS at screening 1-19, No. (%) | “22 (52)” | “7 (58)” | “15 (50)” |
| CPS at screening ≥20, No. (%) | “20 (48)” | “5 (42)” | “15 (50)” |
| Locoregional only, No. (%) | “11 (26)” | “2 (17)” | “9 (30)” |
| Locoregional and distant metastatic, No. (%) | “17 (40)” | “3 (25)” | “14 (47)” |
| Distant metastatic only, No. (%) | “14 (33)” | “7 (58)” | “7 (23)” |
| Sum of target lesion diameters ≤50 mm, No. (%) | “24 (57)” | “8 (67)” | “16 (53)” |
| Sum of target lesion diameters >50 mm, No. (%) | “18 (43)” | “4 (33)” | “14 (47)” |
| Sum of target lesion diameters >70 mm, No. (%) | “11 (26)” | “3 (25)” | “8 (27)” |
| Prior radiotherapy in the LA HNSCC setting, No. (%) | “33 (79)” | “9 (75)” | “24 (80)” |
| Prior platinum-based chemotherapy, No. (%) | “27 (64)” | “12 (100)” | “15 (50)” |

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.2-3"></a>

##### First-line 1500 mg weekly cohort: prior curative-intent therapy

> “At enrollment, 28 patients (66%) had locoregional disease (with or without distant metastases), 39 (93%) had previously received platinum-containing chemotherapy and/or radiation with curative intent, and 22 (52%) had a PD-L1 CPS of 1-19.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.2-4"></a>

##### Dose escalation participants

| Characteristic | Ficerafusp alfa monotherapy (n = 46) | Ficerafusp alfa + pembrolizumab (n = 15) | Total population (N = 61) |
| --- | --- | --- | --- |
| Age (years), median (range) | “61 (43–82)” | “66 (42–81)” | “62 (42–82)” |
| Female, n (%) | “23 (50)” | “5 (33)” | “28 (46)” |
| Male, n (%) | “23 (50)” | “10 (67)” | “33 (54)” |
| ECOG performance status 0, n (%) | “13 (28)” | “4 (27)” | “17 (28)” |
| ECOG performance status 1, n (%) | “33 (72)” | “10 (67)” | “43 (70)” |
| HNSCC, n (%) | “7 (15)” | “7 (47)” | “14 (23)” |
| SCAC, n (%) | “1 (2)” | “8 (53)” | “9 (15)” |
| Number of prior antineoplastic therapies, median (range) | “4 (1–7)” | “2 (1–8)” | “3 (1–8)” |
| Prior anti-EGFR treatment, n (%) | “13 (28)” | “5 (33)” | “18 (30)” |
| Prior anti–PD-(L)1 treatment, n (%) | “21 (46)” | “9 (60)” | “30 (49)” |

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="heading-3.1.2.8.3"></a>

#### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

##### Dose escalation in advanced solid tumors: response in the combination arm

> “With combination therapy, four of 13 evaluable patients (31%) had a confirmed response, including one with head and neck squamous cell carcinoma refractory to anti–PD-1 therapy and cetuximab.”
> “Four patients (HNSCC, n = 2; SCAC, n = 2) achieved a PR (Fig. 1D), with three of the four demonstrating a duration of response exceeding 2 years (range, 10.1–36.7 months), including one response that was ongoing at data cutoff.”
> “Five patients achieved SD, resulting in an objective response rate of 31% (95% CI, 9%–61%) and a clinical benefit rate of 69% (95% CI, 39%–91%) for the combination.”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-3.1.2.8.3-2"></a>

##### Data snapshot of 16 December 2024, 1500 mg weekly cohort: response and 12-month overall survival

> “As of December 16, 2024, 42 pts were treated (71% male, median age: 63 years [range: 31–84]); 39 were efficacy evaluable (EE).”
> “Among the EE pts, the ORR was 54% (21/39; 95% CI: 37–70) in the overall cohort and 64% (18/28; 95% CI: 44–81) in HPV-negative pts.”
> “The 12-month OS rate was 61.5% (95% CI: 44.5–75.7) across the cohort and 60.7% (95% CI: 40.4–76.0) for HPV-negative pts.”

Source: [Chung et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.6017)

<a id="topic-3.1.2.8.3-3"></a>

##### Data snapshot of 20 March 2025, 1500 mg weekly cohort: follow-up

> “As of the data snapshot (March 20, 2025), three patients (8%) remained on study treatment and 36 (92%) had discontinued”
> “The median follow-up was 26.3 months (range, 23.9-29.4).”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.3-4"></a>

##### Data snapshot of 20 March 2025, 1500 mg weekly cohort: confirmed response in HPV-negative participants

> “In the HPV-negative subgroup (n = 28), the confirmed ORR was 54% (n = 15; 95% CI, 34 to 73), including six patients (21%) with CR”
> “Of 15 patients with a confirmed response, 12 (80%) had ≥80% target lesion shrinkage, including 3 PRs with complete resolution of target lesions.”
> “The CBR was 86% (n = 24; 95% CI, 67 to 96).”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.3-5"></a>

##### Data snapshot of 20 March 2025, 1500 mg weekly cohort: response by combined positive score and disease pattern in HPV-negative participants

> “Of patients in the HPV-negative subgroup who had a CPS of 1-19 (n = 13) or ≥20 (n = 15), confirmed ORRs were 54% (95% CI, 25 to 81) and 53% (95% CI, 27 to 79), respectively; three additional patients with CPS ≥20 had an unconfirmed response.”
> “Within the HPV-negative subgroup, responses occurred in 15 of 21 patients (71%) with locoregionally recurrent disease (with or without distant metastases) and 7 of 14 patients (50%) with baseline sum of target lesions >50 mm.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.3-6"></a>

##### Data snapshot of 20 March 2025, 1500 mg weekly cohort: duration of and time to response

> “In the HPV-negative subgroup, median DOR was 21.7 months (95% CI, 6.0 to not estimable [NE]; Figs 2B and 2C), and the probability of maintained response at 12 or 18 months was 65% (95% CI, 40 to 90) and 57% (95% CI, 32 to 83), respectively.”
> “Median time to response was 1.4 months (95% CI, 1.4 to 4.7) in the HPV-negative subgroup and 4.1 months (95% CI, 1.3 to 12.0) in the HPV-positive subgroup.”
> “In HPV-negative patients, 56% of responses occurred by the first imaging assessment (6 weeks after treatment) and four patients converted to CR > 6 months after initiating study treatment.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.3-7"></a>

##### Data snapshot of 20 March 2025, 1500 mg weekly cohort: progression-free and overall survival by HPV status

> “In the HPV-negative and HPV-positive subgroups, median (95% CI) PFS was 9.9 (4.4 to 22.7) and 2.0 (1.0 to 10.0) months, and 12-month PFS rates (95% CI) were 48.0% (28.9 to 67.1) and 20.8% (0 to 46.3), respectively (Fig 3).”
> “Median OS (95% CI) in these subgroups was 21.3 (9.9 to NE) and 16.4 (2.6 to 25.7) months, respectively (Fig 2D).”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.3-8"></a>

##### Assessment of April 2025, 1500 mg weekly cohort: 24-month overall survival

> “At the time of the data snapshot, data were too immature to determine 24-month OS rates; however, subsequent OS assessment in April 2025 showed 24-month OS rates in the HPV-negative and HPV-positive subgroups of 46% (95% CI, 23 to 65) and 27% (95% CI, 1.0 to 53.6), respectively.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.3-9"></a>

##### Data snapshot of 20 March 2025, 1500 mg weekly cohort: survival by combined positive score and performance status

> “In subgroups with CPS 1-19 (n = 19) or ≥20 (n = 20), median (95% CI) PFS was 7.4 (2.7 to NE) and 13.4 (2.8 to 23.2) months, and median OS was 22.0 (7.4 to NE) and 20.6 (6.8 to NE) months, respectively.”
> “In patients with ECOG PS 0 (n = 15) or 1 (n = 24), median PFS was 6.9 (2.7 to NE) and 13.4 (4.2 to 26.4) months, and median OS was 20.6 (7.7 to NE) and 26.4 (6.8 to NE) months, respectively.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.3-10"></a>

##### Data snapshot of 20 March 2025, 1500 mg weekly cohort: HPV-positive participants

> “In the HPV-positive subgroup (n = 11), the confirmed ORR was 27% (n = 3; 95% CI, 6 to 61), including two patients (18%) with CR; the CBR was 55% (n = 6; 95% CI, 23 to 83).”
> “In HPV-positive patients classified as smokers (>10 pack-year smoking history; n = 4) or nonsmokers (n = 7), ORR was 75% and 0%, and CBR was 100% and 29%, respectively.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.3-11"></a>

##### Data snapshot of 9 July 2025, 750 mg weekly cohort: response

> “ORR: 57% (17/30); CR: 10% (3/30)”
> “DCR: 83% (25/30)”
> “Median time to response: 1.6 months”
> “Deep response (≥80% tumor shrinkage): 29% (5/17)”
> “Investigator-assessed best overall response per RECIST 1.1”

Source: [Kaczmar et al. (2025)](https://www.bicara.com/wp-content/uploads/2025/12/750-mg-ESMO-Asia-Congress-2025-12.6.25.pdf)

<a id="topic-3.1.2.8.3-12"></a>

##### Data snapshot of 9 July 2025, 750 mg weekly cohort: response by combined positive score and tumor burden

| Subgroup | Objective response rate |
| --- | --- |
| Combined positive score 1-19 | “73% (8/11)” |
| Combined positive score ≥20 | “47% (9/19)” |
| Sum of target lesion diameters ≤50 mm | “55% (11/20)” |
| Sum of target lesion diameters >50 mm | “60% (6/10)” |
| Sum of target lesion diameters >70 mm | “50% (2/4)” |

Source: [Kaczmar et al. (2025)](https://www.bicara.com/wp-content/uploads/2025/12/750-mg-ESMO-Asia-Congress-2025-12.6.25.pdf)

<a id="topic-3.1.2.8.3-13"></a>

##### Data snapshot of 16 December 2025, 2000 mg every-2-weeks cohort: response

| Outcome | Efficacy-evaluable set (N=27) |
| --- | --- |
| Confirmed objective response rate | “48% (13/27)” |
| Disease control rate | “85% (23/27)” |
| Deep response among responders | “77% (10/13)” |
| Complete response rate | “26% (7/27)” |
| Median time to response | “1.6 months” |
| Objective response rate, combined positive score 1-19 | “57% (8/14)” |
| Objective response rate, combined positive score ≥20 | “39% (5/13)” |

Source: [Zandberg et al. (2026)](https://www.bicara.com/wp-content/uploads/2026/02/Zandberg_2026_MHNCS_Pres_2000-mg-Cohort_Edited.pdf)

<a id="topic-3.1.2.8.3-14"></a>

##### Data snapshot of 16 December 2025, 750 mg and 1500 mg weekly cohorts: efficacy by cohort

> “As of December 16, 2025, 61 HPV-neg pts were treated in two cohorts (750 mg, n=31; 1500 mg, n=30); 58 pts were efficacy evaluable.”

Source: [Wong et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6040)

| Outcome | Ficerafusp alfa 750 mg plus pembrolizumab (N=30) | Ficerafusp alfa 1500 mg plus pembrolizumab (N=28) |
| --- | --- | --- |
| Confirmed objective response rate/complete response rate, n (%) | “17 (57)/4 (13)” | “15 (54)/6 (21)” |
| Responders with ≥80% shrinkage, n (%) | “8/17 (47)” | “12/15 (80)” |
| Median duration of response, months | “NR” | “21.7” |
| Proportion of responses >12 months, n (%) | “9/17 (53)” | “9/15 (60)” |
| Median progression-free survival, months | “6.9” | “9.9” |

Source: [Wong et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6040)

<a id="topic-3.1.2.8.3-15"></a>

##### Data snapshot of 16 December 2025, three cohorts: confirmed response and pooled depth of response

> “As of December 16, 2025, 85 patients with HPV-negative disease were efficacy evaluable across three cohorts (n=30, n=28, and n=27 at 750mg, 1500mg, and 2000mg doses of ficerafusp alfa, respectively). Among these, the confirmed ORRs were 57%, 54%, and 48%, respectively, including 47%, 80%, and 77% of responders achieving a deep response.”
> “In the pooled efficacy evaluable set the percentage of patients with a deep response was 36%, with tumor regression 0 to <80% was 46%, and no tumor regression was 18%.”

Source: [Kaczmar et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6058)

| Outcome | Tumor regression 0 to <80% (N=39) | Tumor regression ≥80%, deep response (N=31) |
| --- | --- | --- |
| Median duration of response, months | “8.2” | “21.9” |
| Duration of response hazard ratio versus <80% regression (95% CI) | “N/A” | “0.27 [0.10, 0.71]” |
| Median progression-free survival, months | “6.5” | “26.4” |
| Progression-free survival hazard ratio (95% CI) | “N/A” | “0.19 [0.09, 0.40]” |
| Median overall survival, months | “14.9” | “NR” |

Source: [Kaczmar et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6058)

<a id="topic-3.1.2.8.3-16"></a>

##### Data snapshot of 31 March 2026, three cohorts: analysis sets and follow-up

> “As of March 31, 2026, 91 patients received the study drug (safety analysis [SA] set) and 85 were evaluable for efficacy (efficacy evaluable [EE] set)”
> “Patient numbers in the SA/EE populations were 31/30, 30/28, and 30/27”
> “Median (95% CI) follow-up was 20 (20-22), 36 (36-43) and 24 (12-27) months”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="topic-3.1.2.8.3-17"></a>

##### Data snapshot of 31 March 2026, three cohorts: response by cohort

| Outcome | Ficerafusp alfa 750 mg weekly | Ficerafusp alfa 1500 mg weekly | Ficerafusp alfa 2000 mg every 2 weeks |
| --- | --- | --- | --- |
| Confirmed objective response rate (95% CI) | “57% (37%-74%)” | “54% (34%-72%)” | “48% (29%-68%)” |
| Deep response among responders | “47% (8/17)” | “80% (12/15)” | “77% (10/13)” |

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="topic-3.1.2.8.3-18"></a>

##### Data snapshot of 31 March 2026, three cohorts: company summary of efficacy by cohort

| Outcome | Ficerafusp alfa 750 mg weekly (n=30) | Ficerafusp alfa 1500 mg weekly (n=28) | Ficerafusp alfa 2000 mg every 2 weeks (n=27) |
| --- | --- | --- | --- |
| Confirmed overall response rate | “57%” | “54%” | “48%” |
| Complete response rate | “13%” | “25%” | “30%” |
| Deep (≥80%) responses | “47%” | “80%” | “77%” |
| Median time to response | “1.6 months” | “1.4 months” | “1.6 months” |
| Median duration of response | “NR (>16.6 months)” | “21.7 months” | “NR (>12.8 months)” |
| Median progression-free survival | “6.9 months” | “9.9 months” | “12.7 months” |
| Median overall survival | “NM (>19.4 months)” | “21.3 months” | “NM (>12.7 months; >23.6 months in patients with > 2-year follow-up)” |

Source: [Bicara Therapeutics three-year overall survival announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/ficerafusp-alfa-plus-pembrolizumab-demonstrated-differentiated)

<a id="topic-3.1.2.8.3-19"></a>

##### Data snapshot of 31 March 2026, 1500 mg weekly cohort: response, duration of response, and 3-year overall survival

> “Response: Confirmed ORR of 54% (CR in 25%) with a rapid median time to response of 1.4 months”
> “After a median follow-up of 36 months, median DOR in the 1500 mg QW cohort was of 21.7 months, with 10% of patients (n=3) remaining on active treatment.”
> “At a median follow-up of 36 months, the 1500 mg QW cohort achieved a clinically meaningful median OS of 21.3 months; the tail of the curve reflects durable long-term survival, highlighted by a landmark 3-year OS rate of 31%”
> “Survival: Median OS of 21.3 months with an estimated 31% of patients alive at 3 years”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="topic-3.1.2.8.3-20"></a>

##### Data snapshot of 31 March 2026, three cohorts: progression-free and overall survival with confidence intervals

| Outcome | Ficerafusp alfa 750 mg weekly | Ficerafusp alfa 1500 mg weekly | Ficerafusp alfa 2000 mg every 2 weeks |
| --- | --- | --- | --- |
| Median progression-free survival (95% CI), months | “6.9 (4.6-NE)” | “9.9 (4.4-22.7)” | “12.7 (4.9-NE)” |
| Median overall survival (95% CI), months | “Not mature” | “21.3 (9.9-33.6)” | “Not mature” |

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="topic-3.1.2.8.3-21"></a>

##### Data snapshot of 31 March 2026, three cohorts: confirmed response by combined positive score, tumor burden, and extent of disease

| Subgroup, % (n/N) | Ficerafusp alfa 750 mg weekly (n=30) | Ficerafusp alfa 1500 mg weekly (n=28) | Ficerafusp alfa 2000 mg every 2 weeks (n=27) |
| --- | --- | --- | --- |
| Combined positive score 1-19 | “73 (8/11)” | “54 (7/13)” | “57 (8/14)” |
| Combined positive score ≥20 | “47 (9/19)” | “53 (8/15)” | “38 (5/13)” |
| Sum of target lesion diameters ≤50 mm | “55 (11/20)” | “53 (8/15)” | “53 (9/17)” |
| Sum of target lesion diameters >50 mm | “60 (6/10)” | “54 (7/13)” | “40 (4/10)” |
| Sum of target lesion diameters >70 mm | “50 (2/4)” | “43 (3/7)” | “33 (2/6)” |
| Locoregional disease only | “38 (6/16)” | “62 (5/8)” | “50 (7/14)” |
| Distant metastatic disease only | “100 (5/5)” | “29 (2/7)” | “40 (2/5)” |
| Locoregional and distant metastatic disease | “67 (6/9)” | “62 (8/13)” | “50 (4/8)” |

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="topic-3.1.2.8.3-22"></a>

##### Data snapshot of 31 March 2026, three cohorts pooled: outcomes by depth of response

> “A pooled analysis of the EE population across all three dose cohorts evaluated whether a deep response (≥80% shrinkage) predicted prolonged DOR, PFS, and OS compared with standard partial response (PR <80%).”
> “Deep response (≥80% tumor shrinkage) was associated with substantially prolonged DOR compared with PR <80% (HR, 0.31 [95% CI, 0.11-0.84])”
> “65% reduction in the risk of disease progression or death compared with PR <80% (HR, 0.35 [95% CI, 0.15-0.91)”
> “reducing the risk of death by 63% (HR, 0.37 [95% CI, 0.13–1.10])”
> “HRs (95% CI) with additional baseline covariate adjustment are shown.”

Source: [Kaczmar et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Kaczmar_2026_ASCO_Poster-layout_Deep-response_FINAL-APPROVED.pdf)

<a id="topic-3.1.2.8.3-23"></a>

##### Data snapshot of 31 March 2026, three cohorts pooled: median duration of response, progression-free survival, and overall survival by best response

| Best response group | Median duration of response (95% CI), months | Median progression-free survival (95% CI), months | Median overall survival (95% CI), months |
| --- | --- | --- | --- |
| Deep response (n=30) | “31.6 (21.6-NE)” | “36.9 (22.7-NE)” | “Not reached (26.3-NE)” |
| Partial response <80% (n=15) | “8.2 (4.0-NE)” | “10.9 (5.6-NE)” | “33.6 (10.9-NE)” |

Source: [Kaczmar et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Kaczmar_2026_ASCO_Poster-layout_Deep-response_FINAL-APPROVED.pdf)

<a id="topic-3.1.2.8.3-24"></a>

##### Data snapshot of 31 March 2026, three cohorts pooled: progression-free and overall survival with stable or progressive disease

| Best response group | Median progression-free survival (95% CI), months | Median overall survival (95% CI), months |
| --- | --- | --- |
| Stable disease (n=26) | “5.8 (3.6-6.8)” | “11.3 (9.0-20.6)” |
| Progressive disease (n=14) | “1.4 (1.3-1.5)” | “7.3 (2.4-17.1)” |

Source: [Kaczmar et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Kaczmar_2026_ASCO_Poster-layout_Deep-response_FINAL-APPROVED.pdf)

<a id="heading-3.1.2.8.4"></a>

#### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.2.8.4-1"></a>

##### Patient-reported outcomes not assessed in the 1500 mg weekly expansion cohort

> “patient-reported outcomes were not assessed”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="heading-3.1.2.8.5"></a>

#### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

##### Dose escalation in advanced solid tumors: combination arm

> “The MTD was not reached in either cohort.”
> “TRAEs were reported for 87% (40 of 46) and 87% (13 of 15) of patients treated with ficerafusp alfa monotherapy and ficerafusp alfa in combination with pembrolizumab, respectively.”
> “For ficerafusp alfa in combination with pembrolizumab, the most common TRAEs were acneiform dermatitis (73%; 11 of 15), fatigue (53%; eight of 15), epistaxis (40%; six of 15), pruritus (40%; six of 15), and maculopapular rash (40%; six of 15).”
> “For ficerafusp alfa in combination with pembrolizumab, serious TRAEs included grade 3 anemia (n = 1), grade 3 stomatitis with grade 3 atrial fibrillation (n = 1), and grade 3 stomatitis with grade 3 pneumonitis (n = 1).”
> “Two patients treated with ficerafusp alfa in combination with pembrolizumab discontinued both drugs because of grade 3 reactive lichen planus and grade 3 atrial fibrillation, respectively. No grade 4 TRAEs or treatment-related deaths were observed in either cohort.”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-3.1.2.8.5-2"></a>

##### Data snapshot of 20 March 2025, 1500 mg weekly cohort: summary of treatment-related adverse events

| Safety outcome | Participants (N = 42), No. (%) |
| --- | --- |
| Grade 3 or 4 treatment-related adverse event | “20 (48)” |
| Treatment-related adverse event leading to ficerafusp alfa discontinuation | “5 (12)” |
| Treatment-related adverse event leading to death | “0” |

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.5-3"></a>

##### Data snapshot of 20 March 2025, 1500 mg weekly cohort: treatment-related adverse events by grade

| Treatment-related adverse event | Any grade | Grade 1/2 | Grade 3 | Grade 4 |
| --- | --- | --- | --- | --- |
| Any treatment-related adverse event | “40 (95)” | “20 (48)” | “19 (45)” | “1 (2)” |
| Dermatitis acneiform | “32 (76)” | “27 (64)” | “5 (12)” | “0” |
| Fatigue | “19 (45)” | “18 (43)” | “1 (2)” | “0” |
| Pruritus | “18 (43)” | “17 (40)” | “1 (2)” | “0” |
| Anemia | “15 (36)” | “9 (21)” | “6 (14)” | “0” |
| Stomatitis | “11 (26)” | “9 (21)” | “2 (5)” | “0” |
| Infusion-related reaction | “8 (19)” | “7 (17)” | “1 (2)” | “0” |
| Epistaxis | “6 (14)” | “6 (14)” | “0” | “0” |
| Gingival bleeding | “6 (14)” | “6 (14)” | “0” | “0” |
| Colitis | “5 (12)” | “2 (5)” | “3 (7)” | “0” |
| Tracheal hemorrhage | “2 (5)” | “1 (2)” | “1 (2)” | “0” |
| Pericarditis | “1 (2)” | “0” | “0” | “1 (2)” |

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.5-4"></a>

##### Data snapshot of 20 March 2025, 1500 mg weekly cohort: overall incidence, interruptions, and discontinuations

> “Patients received a median of six cycles (IQR, 3-12) of ficerafusp alfa and six cycles (IQR, 3-10) of pembrolizumab.”
> “Grade 3 TRAEs occurred in 19 patients (45%), and one patient (2%) had a grade 4 TRAE. The most common grade ≥3 TRAEs were anemia (six [14%]) and acneiform dermatitis (five [12%]); all other grade ≥3 TRAEs occurred in ≤3 patients. No fatal TRAEs were reported.”
> “After TRAEs, ficerafusp alfa treatment was interrupted in 20 patients (48%), due to grade 3 TRAEs in 14 patients (most frequently anemia [n = 4], acneiform dermatitis [n = 4], and colitis [n = 3]). TRAEs led to ficerafusp alfa discontinuation in five patients (12%). No TRAE led to discontinuation in more than one patient.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.5-5"></a>

##### Data snapshot of 20 March 2025, 1500 mg weekly cohort: dermatologic events including acneiform dermatitis

> “Dermatologic TRAEs occurred at any grade in 36 patients (86%); the most frequent were acneiform dermatitis (32 [76%]) and pruritus (18 [43%]). Eight patients (19%) had a grade 3 dermatologic TRAE. Ficerafusp alfa was interrupted because of dermatologic TRAEs in eight patients (19%). Supportive care administered by investigators included topical steroid and antibiotics. No patient discontinued treatment because of dermatitis acneiform or rash TRAEs.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.5-6"></a>

##### Data snapshot of 20 March 2025, 1500 mg weekly cohort: bleeding events

> “Bleeding-related TRAEs occurred at any grade in 14 patients (33%); the most frequent were epistaxis (six [14%]), gingival bleeding (six [14%]), and hematuria (four [10%]). One patient (2%) had a grade 3 bleeding-related TRAE; none reached grade ≥4. Bleeding-related TRAEs led to interruption of ficerafusp alfa in two patients (5%); no discontinuations occurred.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.5-7"></a>

##### Data snapshot of 20 March 2025, 1500 mg weekly cohort: anemia and infusion-related reactions

> “Anemia TRAEs occurred at any grade in 15 patients (36%) and reached grade 3 in six (14%); no grade ≥4 events occurred. Anemia TRAEs led to interruption of ficerafusp alfa in four patients (10%) and discontinuation in two patients (5%). Supportive care administered by investigators included iron supplementation and transfusion. IRR TRAEs occurred in eight patients (19%), including grade 3 IRR in one patient (2%), and led to ficerafusp alfa interruption in two (5%); no discontinuations occurred.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.5-8"></a>

##### Data snapshot of 20 March 2025, 1500 mg weekly cohort: treatment-emergent adverse events and deaths

| Safety outcome | Participants (N = 42), n (%) |
| --- | --- |
| Grade ≥3 treatment-emergent adverse event | “33 (79)” |
| Treatment-emergent adverse event leading to ficerafusp alfa discontinuation | “9 (21)” |
| Treatment-emergent adverse event leading to death | “3 (7)” |

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.5-9"></a>

##### Data snapshot of 9 July 2025, 750 mg weekly cohort: treatment-related adverse events

| Preferred term, n (%) | Any grade (N=31) | Grade 3 (N=31) |
| --- | --- | --- |
| Any treatment-related adverse event | “31 (100)” | “13 (42)” |
| Dermatitis acneiform | “26 (84)” | “1 (3)” |
| Pruritus | “12 (39)” | “1 (3)” |
| Stomatitis | “10 (32)” | “3 (10)” |
| Epistaxis | “10 (32)” | “1 (3)” |
| Anemia | “8 (26)” | “3 (10)” |
| Hypokalemia | “7 (23)” | “2 (6)” |

Source: [Kaczmar et al. (2025)](https://www.bicara.com/wp-content/uploads/2025/12/750-mg-ESMO-Asia-Congress-2025-12.6.25.pdf)

<a id="topic-3.1.2.8.5-10"></a>

##### Data snapshot of 9 July 2025, 750 mg weekly cohort: discontinuations and deaths

| Safety outcome | Safety set (N=31) |
| --- | --- |
| Treatment-related adverse event leading to ficerafusp alfa discontinuation | “2 (6%)” |

Source: [Kaczmar et al. (2025)](https://www.bicara.com/wp-content/uploads/2025/12/750-mg-ESMO-Asia-Congress-2025-12.6.25.pdf)

> “No treatment-related deaths were reported”
> “n=1 each for TEAEs leading to dose reduction and discontinuation.”

Source: [Kaczmar et al. (2025)](https://www.bicara.com/wp-content/uploads/2025/12/750-mg-ESMO-Asia-Congress-2025-12.6.25.pdf)

<a id="topic-3.1.2.8.5-11"></a>

##### Data snapshot of 16 December 2025, 2000 mg every-2-weeks cohort: treatment-emergent adverse events related to ficerafusp alfa

| Event | Any grade (N=30) | Grade 3 (N=30) |
| --- | --- | --- |
| Any related treatment-emergent adverse event | “29 (97%)” | “16 (53%)” |
| Dermatitis acneiform | “24 (80%)” | “3 (10%)” |
| Anemia | “14 (47%)” | “8 (27%)” |
| Stomatitis | “11 (37%)” | “3 (10%)” |
| Pruritus | “11 (37%)” | “1 (3%)” |
| Nausea | “9 (30%)” | “1 (3%)” |

Source: [Zandberg et al. (2026)](https://www.bicara.com/wp-content/uploads/2026/02/Zandberg_2026_MHNCS_Pres_2000-mg-Cohort_Edited.pdf)

<a id="topic-3.1.2.8.5-12"></a>

##### Data snapshot of 16 December 2025, 2000 mg every-2-weeks cohort: discontinuations, grade 4 and 5 events, and deaths

| Safety outcome | Safety set (N=30) |
| --- | --- |
| Treatment-related adverse event leading to ficerafusp alfa discontinuation | “3 (10%)” |

Source: [Zandberg et al. (2026)](https://www.bicara.com/wp-content/uploads/2026/02/Zandberg_2026_MHNCS_Pres_2000-mg-Cohort_Edited.pdf)

> “1 patient had a grade 4 event (hypokalemia); no grade 5 events occurred.”
> “No treatment-related deaths were reported”

Source: [Zandberg et al. (2026)](https://www.bicara.com/wp-content/uploads/2026/02/Zandberg_2026_MHNCS_Pres_2000-mg-Cohort_Edited.pdf)

<a id="topic-3.1.2.8.5-13"></a>

##### Data snapshot of 31 March 2026, three cohorts: treatment-related adverse events by grade and cohort

| Preferred term, n (%) | 750 mg weekly (N=31), any grade | 750 mg weekly, grade 3 | 1500 mg weekly (N=30), any grade | 1500 mg weekly, grade 3 | 2000 mg every 2 weeks (N=30), any grade | 2000 mg every 2 weeks, grade 3 |
| --- | --- | --- | --- | --- | --- | --- |
| Any treatment-related adverse event | “31 (100)” | “11 (35)” | “28 (93)” | “15 (50)” | “29 (97)” | “16 (53)” |
| Dermatitis acneiform | “27 (87)” | “1 (3)” | “23 (77)” | “4 (13)” | “24 (80)” | “3 (10)” |
| Pruritus | “13 (42)” | “1 (3)” | “16 (53)” | “1 (3)” | “11 (37)” | “1 (3)” |
| Anemia | “8 (26)” | “3 (10)” | “13 (43)” | “7 (23)” | “15 (50)” | “8 (27)” |
| Fatigue | “13 (42)” | “0 (0)” | “11 (37)” | “1 (3)” | “12 (40)” | “1 (3)” |
| Stomatitis | “13 (42)” | “4 (13)” | “8 (27)” | “0” | “11 (37)” | “3 (10)” |
| Epistaxis | “11 (35)” | “1 (3)” | “5 (17)” | “0” | “12 (40)” | “0” |
| Mouth bleeding | “8 (26)” | “1 (3)” | “0” | “0” | “4 (13)” | “0” |
| Infusion-related reaction | “6 (19)” | “1 (3)” | “4 (13)” | “1 (3)” | “7 (23)” | “0” |

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="topic-3.1.2.8.5-14"></a>

##### Data snapshot of 31 March 2026, three cohorts: discontinuations, grade 4 events, and deaths

> “Dose discontinuations due to ficerafusp alfa-related TEAEs in the 750mg QW, 1500mg QW and 2000mg Q2W dose cohorts were reported in 2 (6%), 3 (10%) and 2 (7%) patients, respectively. No patient had a grade 5 TEAE related to ficerafusp alfa.”
> “1 patient had grade 4 hypokalemia.”
> “1 patient had grade 4 pericarditis.”
> “No new safety signals were observed in any dose cohort with longer follow-up”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="heading-3.1.2.9"></a>

### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

#### Summary

BCA101X1101 is an open-label, nonrandomized, single-arm phase 1/1b trial with investigator-assessed response; the authors state that the single-arm design makes it “difficult to isolate the contribution of individual treatment components”, and comparisons with KEYNOTE-048 are cross-trial. The 1500 mg weekly cohort enrolled participants in the United States and Canada only, did not assess patient-reported outcomes, and did not routinely collect subsequent therapy. The three first-line dose cohorts were analyzed as separate HPV-negative expansion cohorts of 30, 28, and 27 evaluable participants under a Simon two-stage design, with PD-L1 CPS assessed locally by 22C3 “or other validated assay” and HPV-positive participants of the 1500 mg cohort excluded from the integrated analysis. Duration of response and OS are immature in the 750 mg weekly and 2000 mg every 2 weeks cohorts; in the 2000 mg cohort, 12 of 27 evaluable participants had a median follow-up of 11.7 months. The depth-of-response analysis was post hoc, with small subgroups and a threshold that is not validated. The dose-escalation results come from 15 combination-arm participants with heterogeneous tumors and prior therapy.

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027); [Bicara Therapeutics three-year overall survival announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/ficerafusp-alfa-plus-pembrolizumab-demonstrated-differentiated); [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf); [Kaczmar et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Kaczmar_2026_ASCO_Poster-layout_Deep-response_FINAL-APPROVED.pdf); [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-3.1.2.9-2"></a>

#### Single-arm design, limited geographic scope, and missing subsequent-therapy data

> “Limitations of this study include its single-arm design, which makes it difficult to isolate the contribution of individual treatment components. Although baseline characteristics of HPV-negative and HPV-positive subgroups were generally well balanced, the study design and limited geographic scope (the United States and Canada) may have introduced bias, and patient-reported outcomes were not assessed. Additionally, information on subsequent treatment after study discontinuation was not collected routinely and could not be analyzed.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.9-3"></a>

#### Open-label, nonrandomized design with investigator-assessed response

> “This open-label, multicenter, prospective, nonrandomized, first-in-human, phase I/Ib study”
> “investigator-assessed according to RECIST v1.1”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.9-4"></a>

#### Cross-trial comparisons with historical controls

> “With the caveats of cross-trial comparisons, the ORR of 54% with ficerafusp alfa plus pembrolizumab in the HPV-negative subgroup compares favorably with the ORR of 19% with pembrolizumab monotherapy in patients with CPS ≥1 in the KEYNOTE-048 phase III trial.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

> “No head-to-head studies have been conducted, and cross-trial comparisons differences in molecule composition, trial design, and patient population and characteristics.”

Source: [Bicara Therapeutics three-year overall survival announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/ficerafusp-alfa-plus-pembrolizumab-demonstrated-differentiated)

<a id="topic-3.1.2.9-5"></a>

#### Immature duration of response and survival in the 750 mg and 2000 mg cohorts

> “While DOR data are immature for the 750 mg QW and 2000 mg Q2W cohorts”
> “Data maturation reflects a bimodal enrollment distribution: in the initial 15 EE patients (median follow-up, 27 months), median OS was not reached (95% CI, 9-NE; median has surpassed 23.6 months). The remaining 12 EE patients had a median follow-up of 11.7 months.”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="topic-3.1.2.9-6"></a>

#### Local PD-L1 testing and exclusion of HPV-positive participants from the dose-cohort analyses

> “The 1500 mg QW cohort also enrolled HPV-positive patients, who were not included in the current analysis.”
> “PD-L1 CPS was assessed locally in archival or fresh samples using the 22C3 immunohistochemistry or other validated assay.”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="topic-3.1.2.9-7"></a>

#### Post hoc depth-of-response analysis with an unvalidated threshold

> “This was a post hoc exploratory analysis limited by small sample sizes in each subgroup”
> “Depth of response categories are not validated and a unified standard threshold for deep response has not been established”

Source: [Kaczmar et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Kaczmar_2026_ASCO_Poster-layout_Deep-response_FINAL-APPROVED.pdf)

<a id="topic-3.1.2.9-8"></a>

#### Small sample and heterogeneous population in dose escalation

> “The findings presented here should be interpreted with recognition of the limited sample size and the heterogeneity of the population under study in this phase I clinical trial.”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

## Related pages
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Terms and abbreviations](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations.md)
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: References](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references.md)
